Clinical Trials

CTTI Releases Recommendations for Decentralized Trials


Currently, clinical trials are conducted at a center where the subjects have to return for study visits. This can be burdensome and may slow down enrollment or lead to reduced compliance or retention. In decentralized trials (DCT), subjects may meet study requirements without the need to return to the study site. CTTI has released its recommendations for DCT.

FDA Releases New Guidance Document on Revised Common Rule



The Federal Policy for the Protection of Human Subjects, also known as the “Common Rule,” specifies the requirements for the protection of human subjects in U.S. Department of Health and Human Services (HHS) sponsored clinical trials. A final rule published to the Federal Register in January 2017 revised the Common Rule, which has a compliance date of January 21, 2019.